HomeProductsBioactive CompoundsCell CycleKinesinIspinesib
Chemical structure of CAS 336113-53-2

Ispinesib

CAS No.336113-53-2
MDL No.N/A
MFC30H33ClN4O2
MW517.10
InChI KeyQJZRFPJCWMNVAV-HHHXNRCGSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methylbenzamide is a benzamide.

CAS No.336113-53-2
Product NameIspinesib

Biological Targets

KIF11

Associated Conditions

cancer·breast neoplasm·renal cell carcinoma·rectum cancer·ovarian cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Mechanism of inhibition of human KSP by ispinesib.

Biochemistry • Vol. 47, Issue 11 • 2008
PMID: 18290633DOI: 10.1021/bi702061g

A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).

Investigational new drugs • Vol. 26, Issue 3 • 2008
PMID: 18196204DOI: 10.1007/s10637-007-9103-2

Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.

Investigational new drugs • Vol. 26, Issue 3 • 2008
PMID: 18038218DOI: 10.1007/s10637-007-9098-8

A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.

Investigational new drugs • Vol. 26, Issue 3 • 2008
PMID: 17962907DOI: 10.1007/s10637-007-9097-9

Documentation

Similar Products